TP53-EphA-2-CAR-DC
Phase 1Biologic
Novo NordiskTP53-EphA-2-CAR-DC is one of 13 biologic programs targeting Malignant Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Malignant Tumors
#DrugCompanyPhaseTrials
1Stivarga
BayerPhase 2
Beyfortus
BeiGenePhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Taxotere
AAvyxa
Phase 2
Ifinatamab Deruxtecan
Daiichi SankyoPhase 2
LBL-007
BeiGenePhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Abraxane
Bristol-Myers SquibbPhase 1
Anti-PD-1 Antibody
Boehringer IngelheimPhase 1
Anti-CTLA4 Monoclonal Antibody
Novo NordiskPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Tumors1 trial
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Recruiting·—·Phase 1·NCT05631886·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TP53-EphA-2-CAR-DC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company